We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Vircell S.L.

  Gold Vircell is a biotechnology company specialized in the development and production of ready-to-use reagents for the dia... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
06 Dec 2020 - 08 Dec 2020
Virtual Venue

New Monotest Diagnoses Risk of Invasive Aspergillosis

By LabMedica International staff writers
Posted on 12 Nov 2020
Print article
Image:  ASPERGILLUS GALACTOMANNAN Ag VIRCLIA® MONOTEST (Photo courtesy of Vircell S.L.)
Image: ASPERGILLUS GALACTOMANNAN Ag VIRCLIA® MONOTEST (Photo courtesy of Vircell S.L.)
A new monotest using chemiluminescence, meets the need for the immediate testing of individual samples for patients at risk of invasive aspergillosis, without resorting to batching, cumulating samples, or sending out to an external laboratory.

Aspergillus sp. is one of the most ubiquitous of the airborne saprophytic fungi. With the increase in the number of immune-suppressed patients, there has been a dramatic increase in severe and usually fatal invasive aspergillosis or invasive candidiasis, now one of the most common mold infections worldwide. Invasive Aspergillus Infection (IAI) is an important life-threatening infection in immune-compromised patients, especially those with prolonged neutropenia, allogeneic hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT). In immune-competent hosts, IAI is involved in chronic obstructive pulmonary, Large Burned patients, cirrhosis, corticosteroid treatment, most of them located in Intensive Care Units.

Diagnosis of IAI by conventional culture-based methods show clear deficiencies especially in sensitivity and speed: Confirmation with culture occurs in less than 50% of cases due to the frequent negative results of blood cultures and the difficulty of obtaining deep tissue samples or fluids ordinarily sterile. The availability of effective antifungal agents determines the need for rapid and accurate diagnosis. Therefore, it is essential to implement the diagnosis of invasive mycosis with non-culture-based techniques among which biomarkers are already an essential part.

Currently, the most commonly biomarker used in the case of Aspergillus is the Galactomannan. Galactomannan is a useful diagnostic test for the investigation of invasive aspergillosis in patients with a suggestive clinic. It can be done not only in blood but also in CSF, BAL or peritoneal fluid. Its systematic and periodic use is not recommended in non-symptomatic hematological patients who have been receiving antifungal prophylaxis. However, the format currently marketed by a microtiter plate capture ELISA makes it very difficult to use the test with only one or a few samples. The ELISA method is useful when studying a large number of patients at risk of invasive aspergillosis in a systematic way. New formats are now needed to facilitate its use with a single sample. These new systems must be able to quantify the fungal load and be easy to carry out. One model would be the new immunochromatography based on “Lateral Flow”, which is a very simple, but difficult to quantify technique.

Now, the VirClia Aspergillus Galactomannan AG, a new monotest using chemiluminescence developed by Vircell S.L. (Granada, Spain), could respond to these new diagnostic needs for testing individual samples immediately, without the need for batching, cumulating samples or sending out to an external laboratory. The VirClia Aspergillus Galactomannan AG has been successfully evaluated internally and externally against a commercially available ELISA reference assay and showed a 91% correlation.

Print article

Channels

Copyright © 2000-2020 Globetech Media. All rights reserved.